Forte Biosciences Announces Positive Data From Celiac Disease Study, Stock Climbs In Pre-Market

(RTTNews) - Forte Biosciences, Inc. (FBRX), Monday announced positive data from a Phase 1b trial in celiac disease for lead program FB102, showing statistically significant benefit on the composite histological VCIEL endpoint.

During the study, the company noted change in the density of CD3-positive T cells, or IELs, as well as mean change in the Vh:Cd ratio.

Also, gluten challenge induced GI symptoms based on patient diaries/AE collection demonstrated a 42 percent benefit for FB102 treated subject.

CEO Paul Wagner stated that the company has initiated Phase 2 celiac disease study with a topline readout expected in 2026.

Additionally, the topline results of the FB102 vitiligo study are expected to be readout in the first half of 2026.

In the pre-market hours, Forte's stock is trading at $18.76, up 27.97 percent on the Nasdaq.